The update was based on data from the phase 3 PSO-LONG trial, a randomized, double-blind, vehicle-controlled study that evaluated the long-term use of Enstilar Foam in 545 adults. The Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . The long-term, vehicle-controlled, double-blind, phase 3 PSO-LONG trial compared twice-weekly Enstilar foam ...

THORNHILL, ON, Dec. 3, 2018 /CNW/ - LEO Pharma Canada has announced that as of December 1 st, 2018, Enstilar ® has been added as a Regular Benefit through the Alberta Drug Benefit List. Enstilar ® ...

The FDA has expanded the approval for Taclonex Topical Suspension and Enstilar Foam, two plaque psoriasis therapies to include younger patients. The Food and Drug Administration (FDA) has expanded the ...